PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Globe Newswire•05/10/2026•08:00 ET
0
Key Highlights
- ➤PMV appoints Matt Eckler, Ph.D., to its Board of Directors
- ➤PMV completed enrollment in PYNNACLE Phase 2 monotherapy portion
- ➤NDA submission planned for accelerated approval in first quarter of 2027
- ➤Rezatapopt targets platinum-resistant/refractory ovarian cancer with TP53 Y220C mutations
Expert Statements
Laurie Stelzer, Chair of the Board at PMV Pharmaceuticals
“Matt brings deep understanding of the biotechnology sector, including extensive healthcare investment experience. We look forward to his strategic insight and contributions as we advance rezatapopt toward potential commercialization and position PMV Pharma for continued growth and success.”
Matt Eckler, Principal at Samsara BioCapital and Board member at PMV Pharmaceuticals
“I am pleased to join PMV Pharma’s Board at such an important point in its development. Rezatapopt represents a differentiated approach to targeting mutant p53, with the potential to address a significant unmet need for patients with difficult-to-treat cancers. I’m excited to collaborate closely with the Board and management team to help guide the Company through this next phase of growth and unlock the potential of its transformative science.”
Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research
Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027
Get started
Create a free account to read the full story.